

Clerk of the House of Representatives  
Legislative Resource Center  
135 Cannon Building  
Washington, DC 20515  
<http://lobbyingdisclosure.house.gov>

Secretary of the Senate  
Office of Public Records  
232 Hart Building  
Washington, DC 20510  
<http://www.senate.gov/lobby>

# LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

<b>1. Registrant Name</b> <input checked="" type="checkbox"/> Organization/Lobbying Firm <input type="checkbox"/> Self Employed Individual JOHNSON & JOHNSON SERVICES, INC.			
<b>2. Address</b> Address1 ONE JOHNSON & JOHNSON PLAZA Address2 _____ City NEW BRUNSWICK State NJ Zip Code 08933 Country USA			
<b>3. Principal place of business (if different than line 2)</b> City _____ State _____ Zip Code _____ Country _____			
<b>4a. Contact Name</b> _____	<b>b. Telephone Number</b> _____	<b>c. E-mail</b> _____	<b>5. Senate ID#</b> 20686-12
<b>7. Client Name</b> <input checked="" type="checkbox"/> Self <input type="checkbox"/> Check if client is a state or local government or instrumentality JOHNSON & JOHNSON SERVICES, INC.			<b>6. House ID#</b> 303480000

## TYPE OF REPORT

8. Year 2024

Q1 (1/1 - 3/31)

Q2 (4/1 - 6/30)

Q3 (7/1 - 9/30)

Q4 (10/1 - 12/31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report

Termination Date \_\_\_\_\_

11. No Lobbying Issue Activity

## INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13

### 12. Lobbying

INCOME relating to lobbying activities for this reporting period was:

Less than \$5,000

\$5,000 or more  \$ \_\_\_\_\_

Provide a good faith estimate, rounded to the nearest \$10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

### 13. Organizations

EXPENSE relating to lobbying activities for this reporting period were:

Less than \$5,000

\$5,000 or more  \$ 1,520,000.00

**14. REPORTING** Check box to indicate expense accounting method. See instructions for description of options.

**Method A.** Reporting amounts using LDA definitions only

**Method B.** Reporting amounts under section 6033(b)(8) of the Internal Revenue Code

**Method C.** Reporting amounts under section 162(e) of the Internal Revenue Code

Signature

Digitally Signed By: Jane Adams

Date

1/21/2025 5:32:00  
PM

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code BUD

16. Specific lobbying issues

Issues related to:  
 - Contact lens safety, peripheral artery disease, and stroke care, specifically to provisions regarding appropriations report language  
 - Appropriations for Labor Health and Human Services  
 - NIH funding

17. House(s) of Congress and Federal agencies  Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Deana	McRae			<input type="checkbox"/>
Timothy	Swope			<input type="checkbox"/>
Leif	Brierley			<input type="checkbox"/>
Larry	Camm			<input type="checkbox"/>
Jane	Adams			<input type="checkbox"/>
Colleen	Vivaldi			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code HCR

16. Specific lobbying issues

- S 1375/HR 830, "HELP Copays Act", regarding all provisions.  
 - PL 117-169, "The Inflation Reduction Act", regarding provisions impacting drug pricing and implementation.  
 - PL 113-5 "Pandemic All Hazards Preparedness Reauthorization", regarding all provisions.  
 - S 1355/HR 2940, "PASTEUR Act", regarding all provisions.  
 - HR 3723, "Medical Device Electronic Labeling Act", regarding all provisions.  
 - HR 2748, "Contact Lens Prescription Verification Modernization Act", regarding all provisions.  
 - HR 4261, "Amputation Reduction and Compassion Act", regarding all provisions.  
 - S 3131/HR 5539, "ORPHAN Cures Act", regarding all provisions.  
 - HR 5372, "Expanding Access to Seniors Access to Lower Cost Medicines Act of 2023", regarding all provisions.  
 - S 2305, "The Biosimilar Red Tape Elimination Act", regarding all provisions.  
 - HR 1352, "Increasing Access to Biosimilars Act of 2023", regarding all provisions.  
 - HR 7174, "Ensuring Pathways to Innovative Cures (EPIC) Act", regarding all provisions  
 - HR 8574, the "340B Affording Care for Communities and Ensuring a Strong Safety-Net (ACCESS) Act", regarding all provisions  
 - HR 7384, "Creating Hope Reauthorization Act", regarding all provisions  
 - HR 7153/ S 3679 the "Dr. Lorna Breen Health Care Provider Protection Reauthorization Act", regarding all provisions

Issues related to:

- Obesity
- Biosimilars
- Health equity and diversity in clinical trials
- Myopia
- Ambulatory surgical services
- Access to sterilization capacity for medical technologies
- Peripheral artery disease
- Cardiovascular health
- Stroke care
- FDA medical device shortage reporting requirements
- Alternative funding programs
- PBM practices
- Health care workforce wellbeing
- Medicaid Drug Rebate Program
- the SUSTAIN 340B Act

17. House(s) of Congress and Federal agencies  Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS), Office of Management & Budget (OMB), White House Office, Health & Human Services - Dept of (HHS)

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Deana	McRae			<input type="checkbox"/>
Leif	Brierley			<input type="checkbox"/>
Larry	Camm			<input type="checkbox"/>
Timothy	Swope			<input type="checkbox"/>
Riley	Swinehart			<input type="checkbox"/>
Wendy	Sussman			<input type="checkbox"/>
Meghan	Stone			<input type="checkbox"/>
Amy	Pellegrino			<input type="checkbox"/>
Kelly	Waters			<input type="checkbox"/>
Emely	Sanchez			<input type="checkbox"/>
Abigail	Pinkele			<input type="checkbox"/>
Jane	Adams			<input type="checkbox"/>
Colleen	Nivaldi			<input type="checkbox"/>
David	Kavanaugh			<input type="checkbox"/>
Danielle	Mitchell			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code LBR

16. Specific lobbying issues

- Issues related to diversity, equity and inclusion.

17. House(s) of Congress and Federal agencies  Check if None

U.S. HOUSE OF REPRESENTATIVES, Federal Trade Commission (FTC)

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Larry	Camm			<input type="checkbox"/>
Leif	Brierley			<input type="checkbox"/>
Deana	McRae			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code VET

16. Specific lobbying issues

Issues related to Veterans Administration and Veterans Health Administration policy, procurement, and contracting processes for medical technology.

17. House(s) of Congress and Federal agencies  Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Riley	Swinehart			<input type="checkbox"/>
Jane	Adams			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code CSP

16. Specific lobbying issues

Issues related to:  
- Counterfeit healthcare goods  
- Brand protection

17. House(s) of Congress and Federal agencies  Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Leif	Brierley			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code SCI

16. Specific lobbying issues

Issues related to: - Data privacy - Cybersecurity - Artificial intelligence - Robotics
--

17. House(s) of Congress and Federal agencies  Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
--

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Leif	Brierley			<input type="checkbox"/>
Deana	McRae			<input type="checkbox"/>
Riley	Swinehart			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

--

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code CPT

16. Specific lobbying issues

- S 150, "Affordable Prescriptions for Patients Act of 2023", regarding all provisions.  
- S 79/HR 1717, "Interagency Patent Coordination and Improvement Act of 2023", regarding all provisions.  
- Issues related to intellectual property.

17. House(s) of Congress and Federal agencies  Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Timothy	Swope			<input type="checkbox"/>
David	Kavanaugh			<input type="checkbox"/>
Jane	Adams			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None



**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code TAX

16. Specific lobbying issues

§ 866/HR 2673, "American Innovation and R&D Competitiveness Act of 2023", regarding provisions related to research & development expensing.  
Issues related to:  
- OECD proposals on global tax & implementation  
- R&D expensing  
- Corporate tax provisions in TCJA

17. House(s) of Congress and Federal agencies  Check if None

U.S. HOUSE OF REPRESENTATIVES, Treasury - Dept of

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
David	Kavanaugh			<input type="checkbox"/>
Jane	Adams			<input type="checkbox"/>
Kelly	Waters			<input type="checkbox"/>
Riley	Swinehart			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code PHA

16. Specific lobbying issues

- HR 4490, "To amend the Controlled Substances Act to authorize pharmacies to deliver certain controlled substances to an administering practitioner in lieu of delivering such substances to the to the ultimate user, and for other purposes", regarding all provisions.  
- Issues related to drug shortages.

17. House(s) of Congress and Federal agencies  Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Amy	Pellegrino			<input type="checkbox"/>
Wendy	Sussman			<input type="checkbox"/>
Meghan	Stone			<input type="checkbox"/>
Abigail	Pinkele			<input type="checkbox"/>
Timothy	Swope			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code ENV

16. Specific lobbying issues

Issues related to  
- Clean energy  
- Environmental sustainability  
Final Rule - U.S. EPA Rulemaking on National Emission Standards for Hazardous Air Pollutants (NESHAP) for Ethylene Oxide.

17. House(s) of Congress and Federal agencies  Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Kelly	Waters			<input type="checkbox"/>
Riley	Swinehart			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code **BNK**

16. Specific lobbying issues

HR 5488, S 2805, "Protecting Our Courts from Foreign Manipulation Act of 2023", regarding provisions relating to transparency from foreign investors in US litigation.  
Issues related to:  
- Chapter 11 corporate bankruptcy process  
- Litigation reform

17. House(s) of Congress and Federal agencies  Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Riley	Swinehart			<input type="checkbox"/>
Kelly	Waters			<input type="checkbox"/>
Abigail	Pinkele			<input type="checkbox"/>
Larry	Camm			<input type="checkbox"/>
Jane	Adams			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code MMM

16. Specific lobbying issues

Issues related to the Medicaid Drug Rebate Program.

17. House(s) of Congress and Federal agencies  Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Office of Management & Budget (OMB)

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Amy	Pellegrino			<input type="checkbox"/>
Wendy	Sussman			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code LAW

16. Specific lobbying issues

HR 9922, "the Litigation Transparency Act of 2024", regarding all provisions

17. House(s) of Congress and Federal agencies  Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Jane	Adams			<input type="checkbox"/>
Riley	Swinehart			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

**Information Update Page - Complete ONLY where registration information has changed.**

20. Client new address

Address \_\_\_\_\_  
 City \_\_\_\_\_ State \_\_\_\_\_ Zip Code \_\_\_\_\_ Country \_\_\_\_\_

21. Client new principal place of business (if different than line 20)

City \_\_\_\_\_ State \_\_\_\_\_ Zip Code \_\_\_\_\_ Country \_\_\_\_\_

22. New General description of client's business or activities

**LOBBYIST UPDATE**

23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client

First Name	Last Name	Suffix	First Name	Last Name	Suffix
1 Emely	Sanchez		3		
2			4		

**ISSUE UPDATE**

24. General lobbying issue that no longer pertains

**AFFILIATED ORGANIZATIONS**

25. Add the following affiliated organization(s)

Internet Address:

Name	Address				Principal Place of Business (city and state or country)	
	Street Address	State/Province	Zip	Country	City	Country
					State	

26. Name of each previously reported organization that is no longer affiliated with the registrant or client

1 2 3

**FOREIGN ENTITIES**

27. Add the following foreign entities:

Name	Address			Principal place of business (city and state or country)	Amount of contribution for lobbying activities	Ownership percentage in client
	Street Address	State/Province	Country			
				City		%
				State		

28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization

1  
2

3  
4

5  
6

---

**CONVICTIONS DISCLOSURE**

29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery, extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?

No  Yes

Lobbyist Name	Description of Offense(s)
---------------	---------------------------